Natural History and Development of Spondyloarthritis

Natural History and Development of Spondyloarthritis

By Spondylitis Association of America

This study will evaluate the natural history of spondyloarthritis (SpA) in children and adults. Researchers will study early signs and symptoms of axial spondyloarthritis to better understand the cause and progression of this disease, and in addition, compare genetic data of patients with that of healthy family members’ to help identify the genes involved in SpA, and their functions.

Global Spondyloarthritis Summit 2019, Coming Soon

Global Spondyloarthritis Summit 2019, Coming Soon

By Spondylitis Association of America

We’re very excited to announce the first ever Global Spondyloarthritis Summit! Join us online on Friday, May 3rd through Sunday, May 5th 2019.

This online event brings together some of the most respected medical professionals, including renowned rheumatologists, a physical therapist, pain management specialist, and others to discuss the latest treatment options and research in spondyloarthritis.

Join Us For Our First Twitter Chat! Save The Date: Tuesday, February 12th

Join Us For Our First Twitter Chat! Save The Date: Tuesday, February 12th

By Spondylitis Association of America

SAA is hosting a Twitter Chat! Join us Tuesday, February 12th at 6:00pm Pacific Time for conversations on Overcoming Obstacles living with spondylitis can bring. We’ll discuss relationship challenges and the need for support; balancing life, health, and our various responsibilities while practicing good self-care, and more!

SAA’s Helpful Hints: Community Wisdom – Advice for the Newly Diagnosed

SAA’s Helpful Hints: Community Wisdom – Advice for the Newly Diagnosed

By Spondylitis Association of America

Helpful Hints is a recurring feature, aimed at sharing our community’s knowledge and experiences. In this fourth installment, we asked our online community, “What advice would you give others newly diagnosed with spondylitis?” We share a sample of responses with our thanks. We hope you find them helpful!

A New, Non-Biologic Medication Option Being Tested For Those With Active Ankylosing Spondylitis: Results From a Phase 2 Clinical Trial for Filgotinib, a Selective Jack 1 Inhibitor.

A New, Non-Biologic Medication Option Being Tested For Those With Active Ankylosing Spondylitis: Results From a Phase 2 Clinical Trial for Filgotinib, a Selective Jack 1 Inhibitor.

By Spondylitis Association of America

A phase 2 clinical trial assessed the effectiveness and safety of an oral medication, Filgotinib, in patients with active ankylosing spondylitis (AS) who have not responded adequately to, or have been intolerant of, two or more non-steroidal anti-inflammatory drugs (NSAIDs).

RSS
12345678910Last

Stay Informed

Text/HTML

Careers

Visit our careers page for available positions

Contact Us

Spondylitis Association of America

16360 Roscoe Blvd.  Ste. 100
Van Nuys, CA 91406

Email

info@spondylitis.org

Information Requests

(800) 777-8189 U.S. only
or (818) 892-1616
*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.

Give With Confidence

Independent Charities of America